(Brussels, March 27) -- Cancer vaccines are being investigated in early-phase clinical trials around the world, with many of those trials recruiting patients with melanoma. Although tumor regressions have been seen in 10% to 20% of patients with metastatic melanoma, the great promise of cancer vaccines - controlling tumor growth and cancer spread without serious side-effects - remains as yet unrealized. This could be set to change with the publication of a new mouse model technology in Cancer Research, the journal of the American Association of Cancer Research, from a multi-national team led by investigators at the Brussels Branch of the global Ludwig Institute for Cancer Research (LICR).
"Melanoma has been a focus of cancer vaccine development because many melanoma-specific vaccine targets, so-called 'cancer antigens', have been defined," says the study's senior author, LICR's Dr. Benoit Van den Eynde. "However, we have a limited understanding of how most, but not all, melanomas evade an immune system that has been primed to detect and destroy cancer cells carrying one of these defined cancer antigens."
According to Dr. Van den Eynde, this is due in part to the lack of appropriate animal models in which detailed immunological analyses can be performed before and after vaccination. "The models we use to investigate cancer vaccines at the preclinical level either have a defined cancer antigen in a transplanted tumor, or they have an 'original' tumor that doesn't have a defined antigen. However, in human clinical studies, we have original tumors with defined antigens. So there has been a need for a mouse model that more closely follows the human model."
Thus the Institute that first cloned mouse and human cancer antigens, allowing the rational design of cancer vaccines, has developed a model in which melanoma with a defined cancer antigen can be induced. The model has been engineered to have several mutations found to occur together in human mPage: 1 2 Related biology news :1
Contact: Sarah L. White, Ph.D.
Ludwig Institute for Cancer Research
. Scientists harness diptheria toxin and interleukin 2 to help the immune system attack melanoma2
. Why dont all moles progress to melanoma?3
. Molecular markers signal early metastases from ocular melanoma4
. UCSF study shows suppression of telomerase enzyme can inhibit spread of melanoma5
. Signaling proteins may represent biomarkers for melanoma6
. Virginia Tech researcher examining malignant melanoma in horses7
. Stem cell microenvironment reverses malignant melanoma8
. Researchers use trickery to create immune response against melanoma9
. Study estimates melanoma risk in gene mutation carriers10
. Newfound roadblock to interferon effectiveness against malignant melanoma11
. Researchers discover why melanoma is so malignant